IBB News and Press, iShares Biotechnology ETF From 07/18/22

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...

Gilead Sciences started 2022 on a solid foot, as the original outlook for the year was quite underwhelming. This is comforting, yet the composition of the beat, driven by stronger pandemic related sales, is a bit disappointing. Amidst non-demanding valuation and traction with some...

Resubmission of BLA for DAXI for glabellar lines achieved, PDUFA date established for September 8, 2022. The global Botulinum Toxin market is expected to reach $7.71 billion by 2027. Since launch of the RHA Collection, sales reached $100 million, with first-quarter revenue totalin...

Amgen outperformed the U.S. stock market in the last few months and also reported solid first quarter results. In the years to come, earnings per share will grow due to share buybacks as well as top line growth. Until 2030, management is expecting earnings per share to grow in the...

Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria and Chronic inducible urticaria patients in phase 1b studies. One phase 2 study with Barzolvolimab treating Chronic spontaneous urticaria patients has been initiated with second phas...

As companies adjust to inflation, rising interest rates, and a likely economic slowdown, investors are struggling to compute future earnings and the impact on stock valuations. Broadening the sources of stability can help diversify risk and return potential. Geopolitical risk and ...

The private sector balance increased by over $184 billion in June 2022. Credit creation from commercial banks was strong at $193B+. The seasonal pattern is not moving in line with the historical average and continues moving down. Fed rate increases and QT are happening, provid...

The fact is that while the pundits argue about whether we are in a recession or not when it comes to the stock market, the only thing that matters is liquidity—the amount of money available to trade stocks. It’s pretty obvious that money has been moving into IBB aggressi...

Results from the phase 3 NAVIGATE study using Belapectin for the treatment of patients with NASH Cirrhosis without esophageal varices are expected in Q1 of 2024. If the primary endpoint of the phase 3 NAVIGATE study is met, ability to advance Belapectin towards other indications such ...

Biogen is beginning to have a trend change. Biogen is at the bottom of a trading range that goes back 10 years. Now may be a good time to initiate a position with earnings coming soon. As I look at price charts at the end of the week for potential buys or shorts I notice...